Float Short %

3.46

Margin Of Safety %

-15

Put/Call OI Ratio

1.12

EPS Next Q Diff

-0.05

EPS Last/This Y

3.49

EPS This/Next Y

2.26

Price

154.99

Target Price

176.66

Analyst Recom

1.33

Performance Q

7.51

Relative Volume

1.52

Beta

0.28

Ticker: NBIX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	NBIX	149.94	0.95	2.35	11716
2025-11-11	NBIX	147.33	0.98	2.73	11906
2025-11-12	NBIX	146.84	0.97	2.20	11916
2025-11-13	NBIX	144.14	0.97	0.01	11906
2025-11-14	NBIX	144.81	1.02	0.21	11591
2025-11-17	NBIX	143.52	1.03	0.40	11565
2025-11-18	NBIX	139.15	1.03	0.36	11574
2025-11-19	NBIX	138.02	1.05	1.35	11470
2025-11-20	NBIX	138.98	1.04	5.51	12179
2025-11-21	NBIX	141.88	1.03	1.58	12146
2025-11-24	NBIX	140.65	1.25	0.00	8335
2025-11-25	NBIX	143.56	1.08	0.16	8937
2025-11-26	NBIX	151.62	1.07	0.03	8964
2025-12-01	NBIX	150.98	1.08	0.38	9159
2025-12-02	NBIX	152.5	1.09	0.09	9197
2025-12-03	NBIX	151.85	1.06	0.05	9328
2025-12-04	NBIX	154.25	1.05	0.00	9396
2025-12-05	NBIX	155.51	1.04	1.79	9406
2025-12-08	NBIX	154.95	1.12	1.43	9903
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	NBIX	150.02	42.7	467.7	6.89
2025-11-11	NBIX	147.29	42.7	464.3	6.89
2025-11-12	NBIX	146.80	43.7	481.4	6.90
2025-11-13	NBIX	144.07	43.7	463.7	6.90
2025-11-14	NBIX	144.80	42.7	490.4	6.89
2025-11-17	NBIX	143.56	42.7	474.7	6.89
2025-11-18	NBIX	138.64	42.7	446.0	6.89
2025-11-19	NBIX	138.06	42.7	480.3	6.89
2025-11-20	NBIX	138.95	42.7	492.2	6.89
2025-11-21	NBIX	141.82	42.7	507.9	6.89
2025-11-24	NBIX	141.25	42.7	480.7	6.89
2025-11-25	NBIX	143.53	42.7	502.7	6.89
2025-11-26	NBIX	151.57	42.7	547.7	6.89
2025-12-01	NBIX	150.87	42.7	475.5	6.89
2025-12-02	NBIX	152.48	42.7	496.6	6.89
2025-12-03	NBIX	151.96	42.7	481.1	6.89
2025-12-04	NBIX	154.23	42.7	501.6	6.89
2025-12-05	NBIX	155.51	42.7	494.3	6.89
2025-12-08	NBIX	154.99	42.7	-	6.89
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	NBIX	-7.37	3.13	4.50
2025-11-11	NBIX	-7.37	3.13	4.50
2025-11-12	NBIX	-7.37	3.13	4.24
2025-11-13	NBIX	-7.37	3.13	4.24
2025-11-14	NBIX	-7.37	3.13	4.24
2025-11-17	NBIX	-7.37	5.53	4.24
2025-11-18	NBIX	-7.37	5.53	4.24
2025-11-19	NBIX	-7.37	5.53	4.24
2025-11-20	NBIX	-7.37	5.53	4.24
2025-11-21	NBIX	-7.37	5.53	4.24
2025-11-24	NBIX	-7.37	-1.26	4.24
2025-11-25	NBIX	-7.55	-1.26	4.24
2025-11-26	NBIX	-8.03	-1.26	3.46
2025-12-01	NBIX	-7.72	-1.30	3.46
2025-12-02	NBIX	-7.91	-1.30	3.46
2025-12-03	NBIX	-7.91	-1.30	3.46
2025-12-04	NBIX	-7.91	-1.30	3.46
2025-12-05	NBIX	-8.40	-1.30	3.46
2025-12-08	NBIX	-8.40	-1.25	3.46
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

2.04

Avg. EPS Est. Current Quarter

2.41

Avg. EPS Est. Next Quarter

1.99

Insider Transactions

-8.4

Institutional Transactions

-1.25

Beta

0.28

Average Sales Estimate Current Quarter

805

Average Sales Estimate Next Quarter

773

Fair Value

131.4

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

1.9

Max Drawdown 5-Year %

-42.9

Target Price

176.66

P/E

37.01

Forward P/E

21.89

PEG

1.03

P/S

5.76

P/B

5.14

P/Free Cash Flow

26.06

EPS

4.19

Average EPS Est. Cur. Y

6.89

EPS Next Y. (Est.)

9.15

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

15.95

Relative Volume

1.52

Return on Equity vs Sector %

-12.6

Return on Equity vs Industry %

6.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Neurocrine Biosciences, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 1800

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

stock quote shares NBIX – Neurocrine Biosciences, Inc. Stock Price stock today

news today NBIX – Neurocrine Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NBIX – Neurocrine Biosciences, Inc. yahoo finance google finance

stock history NBIX – Neurocrine Biosciences, Inc. invest stock market

stock prices NBIX premarket after hours

ticker NBIX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NBIX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y